PATENT
Attorney Docket No. LEX-011
(4006/23)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:	Gillies et al.	CONFIRMATION NO.:	8264
SERIAL NO.:	09/780,668	GROUP NO.:	1644
FILING DATE:	February 09, 2001	EXAMINER:	David A. Saunders
TITLE:	ENHANCING THE CIRCULATING HALF-LIFE OF ANTIBODY-BASED FUSION PROTEINS		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or

☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of all wance** under 37 C.F.R. 1.311, and

☐ the requisite Statement is below, **OR**

☐ the requisite fee under 37 C.F.R. 1.17(p), namely **$180.00**, is included herein, or

☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee, AND**

☐ the requisite Statement is below, **AND**

☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Applicants believe no fee is required for entry and consideration of this paper. If a fee is required, please charge Deposit Account 20-0531.

Respectfully submitted,

Brian A. Fairchild, Ph.D.
Agent for Applicants
Testa, Hurwitz & Thibeault, LLP
125 High Street
Boston, Massachusetts 02110

Date: October 30, 2003
Reg. No. 48,645
Tel. No.: (617) 248-7697
Fax No.: (617) 248-7100

2698160_1

EXPRESS MAIL LABEL NO. EV289510878US

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A1	07/348,237	5/5/89	Rosenblum et al.			
	A2	4,196,265	4/1/80	Koprowski et al.			
	A3	4,469,797	9/4/84	Albarella			
	A4	4,676,980	6/30/87	Segal et al.			
	A5	4,816,567	3/28/89	Cabilly et al.			
	A6	4,946,778	8/7/90	Ladner et al.			
	A7	5,019,368	5/28/91	Epstein et al.			
	A8	5,073,627	12/17/91	Curtis et al.			
	A9	5,114,711	5/19/92	Bell et al.			
	A10	5,116,964	5/26/92	Capon et al.			
	A11	5,199,942	4/6/93	Gillis			
	A12	5,225,538	7/6/93	Capon et al.			
	A13	5,225,539	7/6/93	Winter			
	A14	5,258,498	11/2/93	Huston et al..			
	A15	5,314,995	5/24/94	Fell, Jr. et al.			
	A16	5,349,053	9/20/94	Landolfi			
	A17	5,359,035	10/25/94	Habermann			
	A18	5,514,582	5/7/96	Capon et al.			
	A19	5,538,866	7/23/96	Israeli et al.			
	A20	5,541,087	7/30/96	Lo et al.			
	A21	5,543,297	8/6/96	Cromlish, et al.			
	A22	5,552,524	09/03/96	Basinski et al.			
	A23	5,585,089	12/17/96	Queen et al.			
	A24	5,609,846	3/11/97	Goldenberg			
	A25	5,624,821	4/29/97	Winter et al.			

EXAMINER	DATE CONSIDERED

EXPRESS MAIL LABEL NO. EV289510878US

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

	A26	5,639,725	6/17/97	O'Reilly et al.			
	A27	5,645,835	7/8/97	Fell, Jr. et al.			
	A28	5,650,492	7/22/97	Gately et al.			
	A29	5,667,776	9/16/97	Zimmerman et al.			
	A30	5,679,543	10/21/97	Lawlis			
	A31	5,691,309	11/25/97	Basinski et al.			
	A32	5,709,859	1/20/98	Aruffo et al.			
	A33	5,719,266	02/17/98	DiMarchi et al.			
	A34	5,726,044	3/10/98	Lo et al.			
	A35	5,728,552	3/17/98	Fujisawa et al.			
	A36	5,733,876	3/31/98	O'Reilly et al.			
	A37	5,756,461	05/26/98	Stephens			
	A38	5,759,551	6/2/98	Ladd et al.			
	A39	5,770,195	6/23/98	Hudziak et al.			
	A40	5,800,810	9/1/98	Doyle et al.			
	A41	5,807,715	9/15/98	Morrison et al.			
	A42	5,827,516	10/27/98	Urban et al.			
	A43	5,837,682	11/17/98	Folkman et al.			
	A44	5,843,423	12/1/98	Lyman et al.			
	A45	5,854,205	12/29/98	O'Reilly et al.			
	A46	5,856,298	1/5/99	Strickland			
	A47	5,858,347	1/12/99	Bauer et al.			
	A48	5,885,795	3/23/99	O'Reilly et al.			
	A49	5,886,178	3/23/99	Allen et al.			
	A50	5,888,772	3/30/99	Okasinski et al.			
	A51	5,922,685	7/13/99	Rakhmilevich et al.			
	A52	5,994,126	11/30/99	Steinman et al.			
	A53	6,080,409	6/27/00	Laus et al.			

EXAMINER	DATE CONSIDERED

EXPRESS MAIL LABEL NO. EV289510878US

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

	A54	6,086,875	7/11/00	Blumberg et al.			
	A55	6,169,070	1/2/01	Chen et al.			
	A56	6,171,588	1/9/01	Carron et al.			
	A57	6,277,375	8/21/01	Ward			
	A58	6,348,192	2/19/02	Chan et al.			
	A59	6,406,689	6/18/02	Falkenberg et al.			

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B1	0 158 198 A1	10/16/85	EP					Y
	B2	0 211 769 A2	2/25/87	EP					Y
	B3	0 256 714 A2	2/24/88	EP					Y
	B4	0 294 703 A2	12/14/88	EP					Y
	B5	0 308 936 B1	3/29/89	EP					Y
	B6	0 314 317 B1	5/3/89	EP					Y
	B7	0 318 554 B1	6/7/89	EP					Y
	B8	0 319 012 A2	6/7/89	EP					Y
	B9	0 326 120 B1	8/2/89	EP					Y
	B10	0 350 230 A2	1/10/90	EP					Y
	B11	0 375 562 B1	6/27/90	EP					Y
	B12	0 396 387 A2	11/7/90	EP					Y
	B13	0 439 095 A2	7/31/91	EP					Y
	B14	0 511 747 A1	11/4/92	EP					Y
	B15	0 601 043 B1	6/15/94	EP					Y
	B16	0 640 619 A1	3/1/95	EP					Y
	B17	0 668 353 A1	8/23/95	EP					Y
	B18	0 706 799 A2	4/17/96	EP					Y
	B19	0 790 309 A1	8/20/97	EP					Y

EXAMINER	DATE CONSIDERED

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

	B20	21725/88	3/23/89	AU					Y
	B21	93100115.3	7/14/93	CN					N
	B22	93100115.3	7/14/93	CN				Y	Y
	B23	37 12985 A1	11/3/88	DE					N
	B24	37 12985	11/2/88	DE				Y	Y
	B25	2 292 382 A	2/21/96	GB					Y
	B26	63-267278	11/4/88	JP					N
	B27	63-267278	11/4/88	JP				Y	Y
	B28	63-267296	11/4/88	JP					N
	B29	63-267296	11/4/88	JP				Y	Y
	B30	0 237 019 A2	9/16/87	EP				English counterpart of JP 63-267296	Y
	B31	WO 86/01533	3/13/86	PCT					Y
	B32	WO 88/00052	1/14/88	PCT					Y
	B33	WO 88/09344	12/1/88	PCT					Y
	B34	WO 89/02922	4/6/89	PCT					Y
	B35	WO 89/09620	10/19/89	PCT				Abstract in English	N
	B36	WO 90/03801	4/19/90	PCT					Y
	B37	WO 91/00360	1/10/91	PCT					Y
	B38	WO 91/04329	04/04/91	PCT					Y
	B39	WO 91/08298	6/13/91	PCT					Y
	B40	WO 91/13166	9/5/91	PCT					Y
	B41	WO 91/14438	10/3/91	PCT					Y
	B42	WO 92/02240	2/20/92	PCT					Y
	B43	WO 92/08495	5/29/92	PCT					Y
	B44	WO 92/08801	5/29/92	PCT					Y
	B45	WO 92/16562	10/1/92	PCT					Y
	B46	WO 93/03157	2/18/93	PCT					Y
	B47	WO 93/10229	5/27/93	PCT					Y

EXAMINER	DATE CONSIDERED

EXPRESS MAIL LABEL NO. EV289510878US

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

	B48	WO 94/24160	10/27/94	PCT					Y
	B49	WO 94/25055	11/10/94	PCT					Y
	B50	WO 95/05468	2/23/95	PCT					Y
	B51	WO 95/21258	8/10/95	PCT					Y
	B52	WO 95/28427	10/26/95	PCT					Y
	B53	WO 95/31483	11/23/95	PCT					Y
	B54	WO 96/04388	02/15/96	PCT					Y
	B55	WO 96/05309	2/22/96	PCT					Y
	B56	WO 96/08570	3/21/96	PCT					Y
	B57	WO 96/31526	10/10/96	PCT					Y
	B58	WO 97/00317	1/3/97	PCT					Y
	B59	WO 97/15666	5/1/97	PCT					Y
	B60	WO 97/20062	6/5/97	PCT					Y
	B61	WO 97/24137	7/10/97	PCT					Y
	B62	WO 97/24440	7/10/97	PCT					Y
	B63	WO 97/26335	7/24/97	PCT					Y
	B64	WO 97/30089	8/21/97	PCT					Y
	B65	WO 97/33617	9/18/97	PCT					Y
	B66	WO 97/33619	9/18/97	PCT					Y
	B67	WO 97/34631	9/25/97	PCT					Y
	B68	WO 97/43316	11/20/97	PCT					Y
	B69	WO 98/00127	1/8/98	PCT					Y
	B70	WO 98/06752	2/19/98	PCT					Y
	B71	WO 98/28427	7/2/98	PCT					Y
	B72	WO 98/30706	7/16/98	PCT					Y
	B73	WO 98/46257	10/22/98	PCT					Y
	B74	WO 98/59244	12/30/98	PCT					Y
	B75	WO 99/02709	01/21/99	PCT					Y

EXAMINER	DATE CONSIDERED

EXPRESS MAIL LABEL NO. EV289510878US

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

	B76	WO 99/03887	01/28/99	PCT					Y
	B77	WO 99/29732	6/17/99	PCT					Y
	B78	WO 99/52562	10/21/99	PCT					Y
	B79	WO 99/53958	10/28/99	PCT					Y
	B80	WO 99/60128	11/25/99	PCT					Y
	B81	WO 99/62944	12/09/99	PCT					Y
	B82	WO 99/66054	12/23/99	PCT					Y
	B83	WO 00/11033	3/2/00	PCT					Y
	B84	WO 00/34317	06/15/00	PCT					Y
	B85	WO 00/40615	7/13/00	PCT					Y
	B86	WO 00/68376	11/16/00	PCT					Y
	B87	WO 00/69913	11/23/00	PCT					Y
	B88	WO 00/78334 A1	12/28/00	PCT					Y
	B89	WO 01/07081 A1	2/1/01	PCT					Y
	B90	WO 01/10912 A1	2/15/01	PCT					Y
	B91	WO 03/015697 A2	2/27/03	PCT					Y

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C1	Abaza et al., (1992), "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization," Journal of Protein Chemistry, 11:5:433-444.
	C2	Abstract XP-002116766, (1996), "Prostaglandins, their inhibitors and cancer," Prostaglandins, Leukotrienes and Essential Fatty Acids, 54:2:83-94.
	C3	Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," Science, 263:235-237.
	C4	Arenberg et al. (1996), "Interferon-γ-inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," J. Exp. Med, 184:981-992.

EXAMINER	DATE CONSIDERED

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

	C5	Bacha et al., (1988), "Interleukin 2 Receptor-Targeted Cytotoxicity Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein," J. Experimental Medicine, 167:612-622
	C6	Bachelot et al., (March 1998), "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion protein with Enhanced Anti-Tumor Properties In Vivo," Proceedings of the Annual Meeting of the American Association for Cancer Research, 39:271, Abstract #1856.
	C7	Barnett et al., (1994), "Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system," Biochimica et Biophysica Acta, 1209:130-139.
	C8	Baselga, et al., (1998), "Recombinant Humanized Anti-HER2 Antibody (Herceptin ™) Enhances the Antitumor activity of Paclitazel and Doxorubicin against HER3/*neu* Overexpressing Human Breast Cancer Xenografts," Cancer Research, 58:2825-2831.
	C9	Batra et al., (1993), "Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life," Mol. Immunol., 30:379-386.
	C10	Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," Proc. Natl. Acad. Sci., 93:7826-7831.
	C11	Becker et al., (1996), "Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins," Proc. Natl. Acad. Sci. USA, 93:2702-2707.
	C12	Beutler et al., (1988), "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator," Ann. Rev. Biochem., 57:505-518.
	C13	Bissery et al., (1997), "The Taxoids," in Cancer Therapeutics: Experimental and Clinical Agents, Teicher ed., 175-193.
	C14	Bjorn et al., (1985), "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins," Cancer Research, 45:1214-1221.
	C15	Boehm et al., (1997), "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance," Nature, 390:404-407.
	C16	Boehm et al., (1998), "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," Biochemical and Biophysical Research Communications, 252:190-194.
	C17	Boissel et al., (1993), "Erythropoietin Structure-Function Relationships," The Journal of Biological Chemistry, 268:15983-15993.
	C18	Brooks et al., (1994), "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," Cell, 79:1157-1164.
	C19	Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," Archives of Biochemistry and Biophysics, 307:2:411-415.
	C20	Burgess et al., (1990), "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," Journal of Cell Biology, 111:2129-2138.

EXAMINER	DATE CONSIDERED

EXPRESS MAIL LABEL NO. EV289510878US

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

	C21	Canfield et al., (1991), "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," Journal of Experimental Medicine, 173:6:1483-1491.
	C22	Cao et al., (1996), "Kringle Domains of Human Angiostatin," The Journal of Biological Chemistry, 271:46:29461-29467.
	C23	Cao et al., (1997), "Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," The Journal of Biological Chemistry, 272:36:22924-22928.
	C24	Capon et al., (1989), "Designing CD4 immunoadhesins for AIDS therapy," Nature, 337:525-531.
	C25	Caton et al., (1986), "Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemagglutinin," The EMBO Journal, 5:7:1577-1587.
	C26	Chan et al., (1991), "Induction of Interferon γ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," J. Exp. Med., pp. 869-879.
	C27	Chang et al., (1989), "Overview of Interleukin-2 as an Immunotherapeutic Agent," Seminars in Surgical Oncology, 5:385-390.
	C28	Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," Journal of Biological Chemistry, 271:23:13349-13355.
	C29	Chaudhary et al., (1988), "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein," Nature, 335:370-372.
	C30	Chaudhary et al., (1989), "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," Nature, 339:394-397.
	C31	Chen et al., (1997), "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," Journal of Immunology, 159:1:351-358.
	C32	Cheon et al., (1994), "High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains," Proc. Natl. Acad. Sci. USA, 91: 989-993.
	C33	Chuang et al., (1993), "Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes," Gynecol. Oncol., 49:291-298.
	C34	Cohen, S. L. et al., (1996), "Human leptin characterization," Nature, 382:589.
	C35	Cole et al., (1997), "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," Journal of Immunology, 159:3613-3621.
	C36	Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 that Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," Proc. Natl. Acad. Sci, 85:7709-7713.
	C37	Colombo et al., (1996), "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," Cancer Research, 56:2531-2534.

EXAMINER	DATE CONSIDERED

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

	C38	D'Amato et al., (1994), "Thalidomide is an inhibitor of angiogenesis," Proc. Natl. Acad. Sci. USA, 91:4082-4085.
	C39	D'Andrea et al., (1992), "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," J. Exp. Med., 176:1387-1398.
	C40	Ding et al., (1988), "Zinc-Dependent Dimers Observed in Crystals of Human Endostatin," Proceedings of the National Academy of Sciences of USA, 95:10443-10448.
	C41	Earnest et al., (1992), "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," J. Cell. Biochem, Supp, 161:156-166.
	C42	Eisenthal, (1990), "Indomethacin up-regulated the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2," Cancer Immunol. Immunotherap. 31:342-348.
	C43	Fell et al., (1991), "Genetic Construction and Characterization of Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," The J. of Immunology, 146:7:2446-2452.
	C44	Fell et al., (1992), "Chimeric L6 antitumor antibody," The J. of Biol. Chem., 267:15552-15558.
	C45	Friedman, J. M. et al., (1998), "Leptin and the regulation of body weight in mammals," Nature, 395:763-770.
	C46	Gasson et al., (1984), "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils," Science, 226:1339-1342.
	C47	Gately et al., (1998), "The Interleukin-12/Interleukin-12 Receptor system: Role in Normal and Pathologic Immune Responses," Annu. Rev. Immunol., 16:495-521.
	C48	Gillessen et al., (1995), "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist," Eur. J. Immunol., 25:200-206.
	C49	Gillies et al., (1989), "Expression of Human Anti-Tetanus Toxoid Antibody in Transfected Murine Myeloma Cells," Bio/Technology, 7:799-804.
	C50	Gillies et al., (1989), "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," J. Immunol. Methods, 125:191-202.
	C51	Gillies et al., (1990), "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," Hum. Antibod. Hybridomas, 1:1:47-54.
	C52	Gillies et al., (1992), "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," Proc. Natl. Acad. Science, 89:1428-1432.
	C53	Gillies et al., (1993), "Biological Activity and In Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," Bioconjugate Chem., 4:230-235.
	C54	Gillies et al., (1998), "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma matastases," J. Immunology, 160:2:6195-6203.

EXAMINER	DATE CONSIDERED

EXPRESS MAIL LABEL NO. EV289510878US

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

	C55	Gillis et al., (1978), "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," Journal of Immunology, 120:6:2027-2032.
	C56	Goeddel et al., (1986), "Tumor Necrosis Factors: Gene Structure and Biological Activities," Pharm. Sciences, pp. 597-609.
	C57	Gren et al., (1983), "A New Type of Leukocytic Interferon," Dokl. Biochem., 269:91-95.
	C58	Griffon-Etienne et al., (1999), "Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications," Cancer Research, 59:3776-3782.
	C59	Grimaldi et al., (1989), "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," Blood, 73:8:2081-2805.
	C60	Guyre et al., (1997), "Increased potency of Fc-receptor-targeted antigens," Cancer Immunol. Immunother., 45:146-148.
	C61	Harris et al., (1993), "Therapeutic Antibodies - the Coming of Age," Tibtech, 11:42-44.
	C62	Harvill et al., (1995), "An IgG3-IL2 Fusion Protein Activates Complement, Binds FcYRI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R," Immunotech., 1:95-105.
	C63	Harvill et al., (1996), "In vivo properties of an IgG3-IL-2 fusion protein: A general strategy for immune potentiation," Journal of Immunology, 157:7:3165-3170.
	C64	Hazama et al., (1993), "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," Vaccine, 11:6:629-636.
	C65	He et al., (1998), "Humanization and Pharmacokinetics of Monoclonal Antibody with Specificity for Both E- and P-Selectin," J. Immunol., 1029-1035.
	C66	Heijnen et al., (1996), "Antigen Targeting to Myeloid-specific Human FcYRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice," J. Clin. Invest., 97:2:331-338.
	C67	Heinzel et al., (1997), "In Vivo Production and Function of IL-12 p40 Homodimers," J. Immunol., 158:4381-4388.
	C68	Hellstrom et al., (1986), "Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas," Proc. Natl. Acad. Sci., 83:18: 7059-7063.
	C69	Henkart, (1985), "Mechanism of Lymphocyte-Mediated Cytotoxicity," Ann. Rev. Immunol., 3:31-58.
	C70	Herrmann et al., (1989), "Hematopoeitic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," Journal of Clinical Oncology, 7:2:159-167.
	C71	Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1.5 Å Resolution," EMBO Journal, 17:6:1656-1664.
	C72	Holden et al., (2001), "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents," Proceedings of the American Association for Cancer Research, 42:683, Abstract No. 3675.

EXAMINER	DATE CONSIDERED

EXPRESS MAIL LABEL NO. EV289510878US

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

	C73	Holden et al., (2001), "Augmentation of Antitumor activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents," Clinical Cancer Research, 7:2862-2869.
	C74	Hoogenboom et al., (1991), "Construction and expression of antibody-tumor necrosis factor fusion proteins," Molecular Immunology, 28:9:1027-1037.
	C75	Hoogenboom et al., (1991), "Targeting of Tumor Necrosis Factor to Tumor Cells Secretion by Myeloma Cells of a Genetically Engineered Antibody-Tumor Necrosis Factor Hybrid Molecule," Biochim. and Biophys. Acta, 1096:4:345-354 (Abstract).
	C76	Hornick et al, (1999), "Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors," Clin. Cancer Res., 5:51-60.
	C77	Hu et al., (1996), "A Chimeric Lym-1/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake[1]," Cancer Research, 56:4998-5004.
	C78	Huck et al., (1986), "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human Cγ genes," Nucleic Acids Research, Vol. 14:4:1779-1789.
	C79	Huse et al., (1989), "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science, 246:1275-1281.
	C80	Ingber et al., (1990), "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," Nature, 348:555-557.
	C81	Jones et al., (1986), "Replacing the complementarity-determining regions in a human antibody with those from a mouse," Nature, 321:6069:522-525.
	C82	Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2," Journal of Biological Chemistry, 262:12:5723-5731.
	C83	Jung et al., (1986), "Activation of human peripheral blood mononuclear cells by anti-T3: Killing of tumor target cells coated with anti-target-anti-T3 conjugates," Proc. Natl. Acad. Sci., 83:4479-4483.
	C84	Junghans et al., (1996), "The protection receptor of IgG catabolism is the B2-micorgobulin-containing neonatal intestinal transport receptor," Proc. Natl. Acad. Sci., 93:11:5512-5516.
	C85	Kang et al., (1991), "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," Proc. Natl. Acad. Sci., 88:11120-11123.
	C86	Kappel et al., (1992), "Regulating gene expression in transgenic animals," Current Opinion in Biotechnology 3:548-553
	C87	Karpovsky et al., (1984), "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFcλ Receptor Antibodies," Journal of Experimental Medicine, 160:6:1686-1701.
	C88	Kim et al., (1997), "An Ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production," Journal Immunology, 158:9:4137-4144.

EXAMINER	DATE CONSIDERED

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

	C89	Kim et al., (1999), "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV," Journal of Interferon and Cytokine Research, 19:77-84.
	C90	Kranz et al., (1984), "Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes," Proc. Natl. Acad. Sci., 81:7922-7926.
	C91	Kuo et al., (2001), "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NC1/Endostatin Domain," Journal of Cell Biology, 152:6:1233-1246.
	C92	LaVallie et al., (1993), "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," Journal of Biological Chemistry, 268:31:23311-23317.
	C93	Lazar et al., (1988), "Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," Molecular and Cellular Biology, 8:3:1247-1252.
	C94	LeBerthon et al., (1991), "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," Cancer Research, 51:2694-2698.
	C95	Lieschke, et al., (1997), "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo," Nature Biotechnology, 15:1:35-40.
	C96	Linsley et al., (1991), "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," Journal of Experimental Medicine, 174:3:561-569.
	C97	Liu et al., (1985), "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes," Proc. Natl. Acad. Sci., 82:8648-8652.
	C98	Liu et al., (1988), "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells," Science, 239:395-398.
	C99	Liu et al., (1998), "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," Blood, 92:10:3730-3736.
	C100	Lo et al., (1998), "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells," Protein Engineering, 11:6:495-500.
	C101	Lode et al., (1998), "Immunocytokines: a promising approach to cancer immunotherapy," Pharmacol. Thera., 80:3:277-292.
	C102	Lode et al., (1998), "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," Blood, 91:5:1706-1715.
	C103	Lode et al., (1999), "Synergy between an antiangiogenic integrin α_v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases," Proc. Natl. Acad. Sci., 96:1591-1596.
	C104	Lode et al., (1999), "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12," Proc. Natl. Acad. Sci., 96:8591-8596.
	C105	Lode et al., (2000), "Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins," Immunological Investigations, 29:2:117-120.

EXAMINER	DATE CONSIDERED

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

	C106	Maloney et al., (1994), "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma," Blood, 84:8:2457-2466.
	C107	Mark et al., (1992), "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins," Journal of Biological Chemistry, 267:36:26166-26171.
	C108	Martinotti et al., (1995), "CD4 T Cells Inhibit in vivo the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," Eur. J. Immunol. 25:137-146.
	C109	Medesan et al., (1997), "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1[1]," J. Immunology, 158:5:2211-2217.
	C110	Mestre et al., (1997), "Retinoids Suppress Epidermal Growth Factor-induced Transcription of Cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," Cancer Research, 57:2890-2895.
	C111	Mosmann et al., (1989), "TH1 and TH2 CELLS: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," Ann. Rev. Immunol, 7:145-173.
	C112	Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," J. Mol. Biol., 247:979-994.
	C113	Mullins et al., (1998), "Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation," Immunopharmacol. Immunotoxicol., 20:4:473-492.
	C114	Murphy et al., (1986), "Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related α-melanocyte-stimulating hormone fusion protein," Proc. Natl. Acad. Sci., 83:8258-8262.
	C115	Murphy, (1988), "Diphtheria-related peptide hormone gene fusions: A molecular gene approach to chimeric toxin development," Immunotoxins, 123-140.
	C116	Nedwin et al., (1985), "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," Nucleic Acids Research, 13:17:6361-6373.
	C117	Netti et al., (1995), "Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery," Cancer Research, 55:5451-5458.
	C118	Netti et al., (1999), "Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules," Proc. Nat. Acad. Sci, 96:3137-3142.
	C119	Neuberger et al., (1984), "Recombinant Antibodies Possessing Novel Effector Functions," Nature, 312:604-608.
	C120	O'Reilly et al., (1994), "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," Cell, 79:315-328.
	C121	O'Reilly et al., (1996), "Angiostatin induces and sustains dormancy of human primary tumors in mice," Nature Medicine, 2:6:689-692.

EXAMINER	DATE CONSIDERED

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

	C122	O'Reilly et al., (1997), "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," Cell, 88:277-285.
	C123	Pastan et al., (1989), "Pseudomonas Exotoxin: Chimeric Toxins," Journal of Biological Chemistry, 264:26:15157-15160.
	C124	Paul et al., (1988), "Lymphotoxin," Ann. Rev. Immunol., 6:407-438.
	C125	Perez et al., (1986), "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target cell antibodies," J. Exp. Medicine, 163:166-178.
	C126	Perez et al., (1989), "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," Journal of Immunology, 142:10:3662-3667.
	C127	Polizzi et al., (1999), "A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts," Cancer Research, 59:1036-1040.
	C128	Putzer et al., (1997), "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," Proc. Nat'l Acad. Sci., 94:20:10889-10894.
	C129	Reisfeld et al., (1996), "Recombinant antibody fusion proteins for cancer immunotherapy," Current Topics in Microbiology and Immunology, 27-53.
	C130	Reisfeld et al., (1997), "Immunocytokines: a new approach to immunotherapy of melanoma," Melanoma Research, 7:2:S99-S106.
	C131	Riethmuller et al., (1994), "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," The Lancet, 343:1177-1183.
	C132	Roessler et al., (1994), "Cooperative interactions between the interleukin 2 receptor α and β chains alter the interleukin 2-binding affinity of the receptor subunits," Proc. Natl. Acad. Sci., 91:3344-3347.
	C133	Roitt et al., (1993), "The Role of TH Cells in the Selection of Effector Mechanisms Directed Against Target Antigens," Immunology, Third Edition, 8.3-8.4.
	C134	Rosenberg, (1988), "Immunotherapy of Cancer Using Interleukin 2: current status and future prospects," Immunology Today, 9:2:58-62.
	C135	Rozwarski et al., (1994), "Structural comparisons among the short-chain helical cytokines," Structure, 2:3:159-173.
	C136	Santon et al., (1986), "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice," Cancer Research, 46:4701-4705.
	C137	Sasaki et al., (1998), "Structure, function and tissue forms of the C-terminal globular domain of collagen XVII containing the angiogenesis inhibitor endostatin," The EMBO Journal, 17:15:4249-4256.
	C138	Sauve et al., (1991), "Localization in human interleukin 2 of the binding site of the α chain (p55) of the interleukin 2 receptor," Proc. Natl. Acad. Sci., 88:4636-4640.

EXAMINER	DATE CONSIDERED

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

	C139	Schnee et al., (1987), "Construction and expression of a recombinant antibody-targeted plasminogen activator," Proc. Natl. Acad. Sci., 84:6904-6908.
	C140	Schoenhaut et al., (1992), "Cloning and Expression of Murine IL-12," Journal of Immunology, 148:11:3433-3340.
	C141	Senter et al., (1988), "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate," Proc. Natl. Acad. Sci., 85:13:4842-4846.
	C142	Shanafelt et al., (2000), "A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo," Nature Biotechnology, 18:1197-1202.
	C143	Sharma et al., (1999), "T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function," Journal of Immunology, 163:5020-5028.
	C144	Shen et al., (1986), "Heteroantibody-Mediated Cytotoxicity: Antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon-λ and is not blocked by human IgG," Journal of Immunology, 137:11:3378-3382.
	C145	Shiff et al., (1995), "Sulindac Sulfide, an Asprin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," Journal of Clinical Investigation, 96:491-503.
	C146	Shin et al., (1990), "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: Potential applications for cellular targeting," Proc. Natl. Acad. Sci., 87:5322-5326.
	C147	Sim et al., (1997), "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," Cancer Research, 57:1329-1334.
	C148	Stevenson et al., (1997), "Conjugation of Human Fcγ in Closed-Hinge or Open-Hinge Configuration to Fab'γ and Analogous Ligands," Journal of Immunology, 158:2242-2250.
	C149	Sulitzeanu et al., (1993), "Immunosuppressive factors in human cancer," Adv. Cancer Research, 60:247-267.
	C150	Taniguchi et al., (1983), "Structure and expression of a cloned cDNA for human interleukin-2," Nature, 302:305-309.
	C151	Tao et al., (1989), "Studies of Aglycosylated Chimeric Mouse IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," Journal of Immunology, 143:8:2595-2601.
	C152	Tao et al., (1993), "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Complement Activation," Journal of Experimental Medicine, 178:2:661-667.
	C153	Teicher et al., (1994), "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents," Int. J. Cancer, 57:920-925.
	C154	The Merck Manual of Diagnosis and Therapy, 990-993, 1278-1283 (17th ed. 1999).
	C155	Till et al., (1988), "An Assay that Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins," Cancer Research, 48:5:1119-1123

EXAMINER	DATE CONSIDERED

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: LEX-011 (4006/23) APPLICANT(S): Gillies et al. SERIAL NO.: 09/780,668 CONF.: 8264 FILING DATE: February 09, 2001 GROUP: 1644

	C156	Till et al., (1988), "HIV-Infected Cells are Killed by rCD4-Ricin A Chain," Science, 242:1166-1168
	C157	Trinchieri, (1994), "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," Blood, 84:4008-4027.
	C158	Vagliani et al., (1996), "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," Cancer Research, 56:467-470.
	C159	Varki et al., (1984), "Antigens Associated with a human lung adenocarcinoma defined by monoclonal antibodies," Cancer Research, 44:681-687.
	C160	Verhoeyen et al., (1988), "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," Science, 239:1534-1536.
	C161	Villunger et al., (1997), "Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance," Blood, 90:1:12-20.
	C162	Watanabe et al., (1997), "Long-term depletion of naive T cells in patients treated for Hodgkin's disease," Blood, 90:9:3662-3672.
	C163	Wen et al., (1993), "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," Blood, 82:1507-1516.
	C164	Williams et al., (1986), "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment," Gene, 43:319-324.
	C165	Williams et al., (1987), "Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein," Protein Engineering, 1:6:493-498.
	C166	Wooley et al., (1993), "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice," Journal Immunology, 151: 6602-6607.
	C167	Wu et al., (1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin," Biochemical and Biophysical Research Communications, 236:651-654.
	C168	Xiang et al., (1997), "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," Cancer Research, 57:4948-4955.
	C169	Zheng et al., (1995), "Administration of noncytolytic IL-10/Fc in muring models of lipopolysaccharide-induced septic shock and allogenic islet transplantation," Journal of Immunology, 154:5590-5600.
	C170	Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," J. Biol. Chem., 269:3469-3474.

EXAMINER	DATE CONSIDERED